Keywords: otc, claritin, potential, reduce, antihistamine, market, over-the-counter
OTC Claritin's potential to reduce the antihistamine market
Article | 08 July 2002
Over-the-counter Claritin (loratadine), from Schering-Plough, has thepotential to significantly reduce the nonsedating antihistamine market, claims a new study from Decision ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
